Deciding who should have thrombolysisBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6920.59a (Published 01 January 1994) Cite this as: BMJ 1994;308:59
- J Rawles
- Medicines Assessment Research Unit, University of Aberdeen, Aberdeen AB9 2ZD.
EDITOR - K S Channer1 and other correspondents2 seem to misunderstand the results of clinical trials of thrombolytic agents. In 17 000 patients in the second international study of infarct survival (ISIS-2) the odds of dying were reduced by 25% by streptokinase compared with placebo (figure).3 With such large numbers the confidence intervals, which indicate where the “true” result is to be found with 95% certainty, are narrow.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial